Cargando…

Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe

BACKGROUND: Little is known about the association of atrial fibrillation symptom burden with quality of life and outcomes. METHODS AND RESULTS: In the Prevention of Thromboembolic Events–European Registry in Atrial Fibrillation (n=6196 patients with atrial fibrillation; mean±SD age, 71.8±10.4 years;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnabel, Renate B., Pecen, Ladislav, Rzayeva, Nargiz, Lucerna, Markus, Purmah, Yanish, Ojeda, Francisco M., De Caterina, Raffaele, Kirchhof, Paulus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015366/ https://www.ncbi.nlm.nih.gov/pubmed/29776959 http://dx.doi.org/10.1161/JAHA.117.007559

Ejemplares similares

Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation
por: Schnabel, Renate B, et al.
Publicado: (2017)

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF (PREvention oF Thromboembolic Events–European Registry in Atrial Fibrillation)
por: Patti, Giuseppe, et al.
Publicado: (2017)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry
por: Schnabel, Renate B, et al.
Publicado: (2023)

Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
por: Boriani, Giuseppe, et al.
Publicado: (2021)

Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
por: Patti, Giuseppe, et al.
Publicado: (2022)

Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death
por: Brady, Paul F., et al.
Publicado: (2022)

Detection of unknown atrial fibrillation by prolonged ECG monitoring in an all-comer patient cohort and association with clinical and Holter variables
por: Jawad-Ul-Qamar, Muhammad, et al.
Publicado: (2020)

Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis( )
por: Diemberger, Igor, et al.
Publicado: (2022)

Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation
por: Chua, Winnie, et al.
Publicado: (2019)

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
por: Renda, Giulia, et al.
Publicado: (2020)

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program
por: Chao, Tze-Fan, et al.
Publicado: (2023)

Genetics of atrial fibrillation—practical applications for clinical management: if not now, when and how?
por: Kany, Shinwan, et al.
Publicado: (2021)

Integrated care of patients with atrial fibrillation: the 2016 ESC atrial fibrillation guidelines
por: Kirchhof, Paulus
Publicado: (2017)

Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank
por: Kany, Shinwan, et al.
Publicado: (2022)

Global Burden of Atrial Fibrillation and Flutter by National Income: Results From the Global Burden of Disease 2019 Database
por: Ohlrogge, Amelie H., et al.
Publicado: (2023)

Catheter ablation in patients with persistent atrial fibrillation
por: Kirchhof, Paulus, et al.
Publicado: (2017)

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
por: Kirchhof, Paulus, et al.
Publicado: (2022)

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)
por: Kirchhof, Paulus, et al.
Publicado: (2014)

Machine learning-based identification of risk-factor signatures for undiagnosed atrial fibrillation in primary prevention and post-stroke in clinical practice
por: Schnabel, Renate B, et al.
Publicado: (2022)

Almanac 2015: atrial fibrillation research in Heart
por: Jawad-Ul-Qamar, Muhammad, et al.
Publicado: (2016)

Recent advances in rhythm control for atrial fibrillation
por: Bond, Richard, et al.
Publicado: (2017)

Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study
por: Chua, Winnie, et al.
Publicado: (2021)

An Introduction to Murine Models of Atrial Fibrillation
por: Riley, Genna, et al.
Publicado: (2012)

Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Self-palpation for detection of paroxysmal atrial fibrillation: Much noise with little signal
por: Rahimi, Kazem, et al.
Publicado: (2020)

PITX2‐dependent gene regulation in atrial fibrillation and rhythm control
por: Syeda, Fahima, et al.
Publicado: (2017)

An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions
por: Chua, Winnie, et al.
Publicado: (2023)

Integrated care in stroke survivors: When and how much?
por: Schnabel, Renate B., et al.
Publicado: (2020)

Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries
por: Russo, Vincenzo, et al.
Publicado: (2022)

Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial
por: Willems, Stephan, et al.
Publicado: (2021)

Depression in Atrial Fibrillation in the General Population
por: Schnabel, Renate B., et al.
Publicado: (2013)

Multiple Biomarkers and Atrial Fibrillation in the General Population
por: Schnabel, Renate B., et al.
Publicado: (2014)

Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
por: Choi, Eue-Keun, et al.
Publicado: (2021)

Adding to the evidence or to the confusion: dual antithrombotic therapy in chronic coronary syndrome and atrial fibrillation
por: Kany, Shinwan, et al.
Publicado: (2021)

The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification
por: Wynn, Gareth J., et al.
Publicado: (2014)

Alcohol and atrial fibrillation: dose matters, not so much the type
por: Csengeri, Dora, et al.
Publicado: (2021)

Mortality Prediction of the CHA(2)DS(2)-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation
por: Morrone, Doralisa, et al.
Publicado: (2020)

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
por: de Groot, Joris R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gavesid100fbe39dbq8lh9vemp